Essential Medical Reading
Your Weekly Roundup of the Most-Read News and Clinical References from Your Peers
FDA Approves Rubraca, First PARP Inhibitor for Prostate Cancer
Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.
Hematology May 25th 2020
ASCO Offers Guidance on Resuming Cancer Care During COVID-19
In this Special Report, the American Society of Clinical Oncology (ASCO) publishes guidance for oncology practices on how to safely restore patient access to diagnostics, treatments, and other critical cancer care services.
Internal Medicine May 25th 2020
Anetumab Ravtansine Shows Encouraging Activity in Multiple Solid Tumor Types
In this Journal of Clinical Oncology study, anetumab ravtansine yielded manageable safety, tolerability, pharmacokinetics, and clinical activity in a study of 148 heavily pretreated patients with mesothelin-expressing solid tumors.
Gastroenterology May 18th 2020
FDA Approves Selpercatinib as First Therapy for Certain Patients With Lung, Thyroid Cancers
Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.
Hematology May 18th 2020
COVID-19: US Scientists Identify 14 Vaccines to Focus On
This roundup of articles highlights the 14 vaccines doctors are targeting in the fight against COVID‑19, in addition to featuring one doctor’s claim that the virus was active in France in December 2019, almost a month earlier than previously believed.
Allergy & Immunology May 11th 2020
Letrozole Pre-Surgery Yields Drastic Biomarker Changes in ER+ DCIS
According to a study featured in the Journal of Clinical Oncology, pre-surgery letrozole led to significant imaging and biomarker changes in postmenopausal patients with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS) in a phase 2 clinical trial.
Internal Medicine May 11th 2020